Apollomics, Inc. (APLM)
NASDAQ: APLM · Real-Time Price · USD
6.13
-0.20 (-3.15%)
Aug 26, 2025, 10:21 AM - Market open
Apollomics Employees
Apollomics had 13 employees as of December 31, 2024. The number of employees decreased by 32 or -71.11% compared to the previous year.
Employees
13
Change (1Y)
-32
Growth (1Y)
-71.11%
Revenue / Employee
$15,231
Profits / Employee
-$4,142,923
Market Cap
6.76M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 13 | -32 | -71.11% |
| Dec 31, 2023 | 45 | 2 | 4.65% |
| Dec 31, 2022 | 43 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
APLM News
- 5 months ago - Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress - GlobeNewsWire
- 5 months ago - Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib - GlobeNewsWire
- 8 months ago - Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia - GlobeNewsWire
- 9 months ago - Apollomics Regains Compliance with Nasdaq's Minimum Bid Price Requirement - GlobeNewsWire
- 1 year ago - Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire
- 1 year ago - Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress - GlobeNewsWire
- 1 year ago - Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial - GlobeNewsWire
- 1 year ago - Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewsWire